Haloperidol Laropharm (Haloperidol)

Haloperidol Laropharm is indicated for several psychiatric conditions where dopamine blockade is beneficial, and it may be used as part of a broader therapeutic strategy that includes psychosocial interventions.

• Schizophrenia, both for acute symptom control and long‑term maintenance therapy, often in combination with other antipsychotics or mood stabilizers as directed by a clinician.
• Acute psychotic episodes of any etiology, where rapid reduction of hallucinations, delusions, or disorganized thinking is required.
• Manic phases of bipolar disorder, particularly when mood elevation is accompanied by psychotic features or severe agitation.
• Severe agitation or aggression that poses a risk to the patient or others, often in emergency or inpatient settings.
• Tourette syndrome with prominent motor tics that have not responded adequately to first‑line therapies.

Haloperidol Laropharm may cause a range of adverse effects, which are generally categorized by frequency and clinical significance. Patients should be monitored regularly for both common and serious reactions.

Common

• Drowsiness or sedation, which may affect alertness and the ability to operate machinery.
• Extrapyramidal symptoms such as tremor, muscle rigidity, or akathisia (inner restlessness).
• Dry mouth and constipation, reflecting anticholinergic activity.
• Blurred vision or dizziness, especially when standing up quickly.

Serious

• Neuroleptic malignant syndrome, a rare but potentially fatal reaction marked by high fever, muscle rigidity, and autonomic instability.
• Tardive dyskinesia, a potentially irreversible movement disorder that can appear after months or years of therapy.
• Significant cardiac arrhythmias, including QT interval prolongation that may predispose to ventricular tachycardia.

When prescribing Haloperidol Laropharm, clinicians consider several precautions to minimize risks and ensure safe use.

• Assess for a history of cardiovascular disease, as haloperidol can affect heart rhythm.
• Evaluate for prior extrapyramidal reactions or movement disorders before initiating therapy.
• Use the lowest effective dose, especially in elderly patients, to reduce sedation and fall risk.
• Monitor blood glucose and lipid levels in patients with diabetes or metabolic syndrome.
• Avoid abrupt discontinuation; taper the dose gradually to prevent withdrawal phenomena.
• Consider pregnancy and lactation status, as safety data are limited.

Haloperidol Laropharm can interact with other medicines, altering its effectiveness or increasing the risk of adverse effects.

Avoid

• Concurrent use with other dopamine antagonists or high‑potency antipsychotics, which may amplify extrapyramidal side effects.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) that can raise haloperidol plasma concentrations.
• Medications that prolong the QT interval, such as certain antiarrhythmics or fluoroquinolone antibiotics.

Use with caution

• CNS depressants like benzodiazepines or opioids, which can increase sedation and respiratory depression.
• Antihypertensive agents, as haloperidol may cause orthostatic hypotension.
• Lithium, because combined therapy may heighten neurotoxic risk.
• Anticholinergic drugs, which may exacerbate dry mouth and constipation.